Squamous cell carcinoma of the prostate

Mohan, Harsh; Bal, Amanjit; Punia, Rajpal Singh; Bawa, Amarpreet Singh

doi:10.1046/j.1442-2042.2003.00580.x

Cited by 44 publications

(29 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Adenocarcinoma of the cervix comprises only about 10-15% of all cervical carcinomas, and 70% are HPV-18 positive [6,7]. Squamous cell carcinoma of the prostate is extremely rare, comprising only 0.5-1% of all diagnosed prostate cancers [8]. Previous studies on HPV and prostate cancer have identified HPV DNA with highly varying prevalences [2][3][4][5]9].…”

Section: Introductionmentioning

confidence: 99%

Human Papillomavirus in Benign Prostatic Hyperplasia and Prostatic Adenocarcinoma Patients

Chen

Waterboer

Keleher

et al. 2011

Pathol. Oncol. Res.

View full text Add to dashboard Cite

The aim of this study was to determine the prevalence of human papillomavirus (HPV) types in tissue and HPV antibodies in prostatic disease. Prostate tissue samples were collected from 51 patients diagnosed with adenocarcinoma and 11 with benign prostatic hyperplasia (BPH). All tissue samples were confirmed by histology. Plasma samples were available for 52 prostate patients. We investigated HPV DNA prevalence by PCR, and PCR positive samples were HPV type determined by sequencing. Prevalence of antibodies against twenty-seven HPV proteins from fourteen different HPV types was assessed in the plasma samples. The HPV DNA prevalence in the tissue samples was 14% (7/51) for prostate cancer samples and 27% (3/11) for BPHs. HPV-18 was the only type detected in tissue samples (10/62). No significant difference in HPV prevalence between the prostate cancer and BPH samples was found. HPV-positive cells were identified in eight of our thirteen prostate tissue slides (3/3 BPH and 5/10 adenocarcinoma) by in situ hybridisation, and the positive cells were found in epithelial cells and peripheral blood cells. Serology data showed no significant increase in levels of antibodies against any of the HPV-18 proteins tested for in prostatic disease patients. Antibodies against HPV-1, HPV-4, HPV-6 and HPV-11 were significantly higher in the group of males with prostatic disease. Our study did not show an association between prostatic disease and either presence of HPV DNA in samples or previous exposure of high-risk HPV.

show abstract

Section: Introductionmentioning

confidence: 99%

Human Papillomavirus in Benign Prostatic Hyperplasia and Prostatic Adenocarcinoma Patients

Chen

Waterboer

Keleher

et al. 2011

Pathol. Oncol. Res.

View full text Add to dashboard Cite

show abstract

“…For male primary UC, various predisposing factors have been reported, including urethral strictures, 2,4,8,9 chronic irritation after intermittent catheterization or urethroplasty, 10–12 external beam radiation therapy, 13 radioactive seed implantation, 14 chronic urethral inflammation urethritis after sexually transmitted diseases (i.e., condylomata associated with human papillomavirus 16), 4,15,16 and congenital origin (i.e., clear cell adenocarcinoma). 17 …”

Section: Discussionmentioning

confidence: 99%

Primary Adenocarcinoma of the Urethra: A Case Report and Review of the Literature

Basiri

Narouie

Moghadasi

et al. 2015

Journal of Endourology Case Reports

View full text Add to dashboard Cite

show abstract

“…Nevertheless, some data are available on potential secondary malignancies in other sites: hematologic malignancies [12,13,35], sarcoma [1,8,10,30,38,40,45,48,50], malignant fibrous histiocytoma [33] and squamous cell carcinoma of prostate [32,34]. Within the larger trials nonconcordant increases in the risk rates for sarcoma [6,44,51], hematologic malignancies [36], urogenital cancer [22], lung cancer [6,24,36], melanoma [36,37], gastrointestinal [36] and cerebral malignancies [36] were reported.…”

Section: Other Second Malignanciesmentioning

confidence: 99%